Class action lawsuits
Johnson Fistel, PLLP is investigating potential claims on behalf of Alto Neuroscience, Inc. (NYSE: ANRO) shareholders against the company's officers and directors who may have breached their fiduciary duties. A federal securities fraud class action complaint alleges that Alto Neuroscience made materially false and misleading statements about its
Class action lawsuits
Alto Neuroscience, Inc. (NYSE: ANRO) faces a securities lawsuit after investors claimed the company made false statements about its product pipeline, ALTO-100. The lawsuit alleges that the company's product was less effective in treating major depressive disorder than investors were led to believe. As a result, investors may
Class action lawsuits
Investors who purchased shares of Alto Neuroscience, Inc. during a specific timeframe have been issued a notice to potentially recover losses due to alleged false and misleading statements made by the company. The Gross Law Firm is leading the class action lawsuit against Alto Neuroscience, Inc. (NYSE: ANRO), claiming that
Nervous system diseases
Klotho Neurosciences, Inc. has announced the evaluation of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity. This expansion complements the company's core programs targeting neurodegenerative diseases and aims to slow biological aging and reduce the burden of age-related diseases. The company is now
Securities law
A national securities law firm, Faruqi & Faruqi, LLP, is investigating potential claims against Alto Neuroscience, Inc. ("Alto" or the "Company") (NYSE: ANRO) and reminding investors of the September 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action. The
Securities law
Alto Neuroscience, Inc. ("Alto" or the "Company"), a leading developer of novel therapies for central nervous system ("CNS") disorders, including major depressive disorder (MDD), has been at the center of a federal securities class action filed against the Company. The suit alleges that Alto
Nervous system diseases
Klotho Neurosciences, Inc., a NASDAQ-listed company, is evaluating the acquisition of technologies aimed at supporting healthy brain function, organ health, and longevity. Building on its core programs targeting brain aging and neurodegenerative diseases, the company is now exploring adjacent technologies that complement its proprietary anti-aging Klotho platform. The goal is
Class action lawsuits
Rosen Law Firm, a global investor rights law firm, has announced the filing of a class action lawsuit on behalf of purchasers of common stock of Alto Neuroscience, Inc. (NYSE: ANRO) in connection with the company's initial public offering (IPO) conducted on February 2, 2024, and subsequent securities
Securities law
Alto Neuroscience, Inc. has been hit with a securities lawsuit alleging that the company and its executives made false statements about the effectiveness of their product pipeline, ALTO-100, in treating major depressive disorder. The lawsuit claims that the defendants misrepresented the clinical, regulatory, and commercial prospects of ALTO-100, leading to
Class action lawsuits
The Gross Law Firm has issued a notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO), urging those who purchased shares of the company during the class period to contact the firm regarding possible lead plaintiff appointment. The allegations against Alto Neuroscience include the company issuing false and misleading statements
Class action lawsuits
Attorney Bronstein, Gewirtz & Grossman, LLC has notified investors that a class action lawsuit has been filed against Alto Neuroscience, Inc. and certain of its officers. The lawsuit seeks to recover damages for alleged violations of federal securities laws on behalf of investors who purchased or acquired Alto common stock
Class action lawsuits
Faruqi & Faruqi, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. ("Alto" or the "Company") and reminds investors of the September 19, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been
